Latest News
-
Monday - October 21, 2019
Bayer at the Annual Biocontrol Industry Meeting 2019:
“Biologicals by Bayer”, leading innovation for organic crop protection solutions » more
-
Wednesday - October 16, 2019
Bayer Animal Health and VLPbio sign global collaboration agreement
Bayer Animal Health to strengthen its technology portfolio for biological products » more
-
Monday - October 14, 2019
Not intended for U.S. and UK Media
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients
A new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTE » more
-
Monday - October 14, 2019
Neptra® receives positive CVMP opinion for launch in Europe
Bayer's Neptra® ear drops solution for dogs treats susceptible strains of common pathogens found in canine otitis externa. » more
-
Thursday - October 10, 2019
Bayer inks deals with eleven startups under G4A Digital Health Partnerships program
Eleven healthcare startup companies to be supported by Bayer’s “G4ADigital Health Partnerships program” to drive forward innovative digital health solutions for patients / Includes financial funding, commercial partnerships in areas of cardiovascular health, oncology, ophthalmology, pulmonology, radiology, digital therapeutics » more
-
Thursday - October 10, 2019
Bayer launches LifeHub UK focused on Artificial Intelligence to optimize data-driven drug discovery and disease diagnosis
Collaborations with external partners will drive development of AI-enabled radiology to enhance patient outcomes / LifeHub UK is the newest member of Bayer’s network of LifeHubs designed to plug into the global innovation ecosystems to solve challenges in health and nutrition » more
-
Tuesday - October 1, 2019
Future of Farming Dialogue 2019 » more
-
Tuesday - October 1, 2019
Ertharin Cousin to become member of Bayer AG Supervisory Board
International expert in the area of nutrition and agriculture / Cousin succeeds Thomas Ebeling, who stepped down at the end of September » more
-
Tuesday - October 1, 2019
New company supported by over USD 55 million in committed funding from Bayer:
Bayer and Arvinas unveil targeted protein degradation joint venture, Oerth Bio
Oerth Bio to utilize Arvinas’ PROTAC® technology to develop innovative new agricultural products to improve crop yields / John Dombrosky announced as CEO of Oerth Bio / Transaction had been formally closed on July 15, 2019 » more
-
Tuesday - October 1, 2019
Future of Farming Dialogue hosted by Bayer:
Bayer committed to shaping a more sustainable food system
Agriculture is part of the solution for climate change / Investing more than 25 billion euros in Crop Science R&D over the next 10 years / Leading Digital Farming platform FieldView on 90 million paid acres this year » more
-
Monday - September 30, 2019
Bayer appoints Ingo Elfering Crop Science CIO and Head of Digital Transformation » more
-
Saturday - September 28, 2019
Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019
Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer
79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications(1,2) / Similar ORR of 75% in patients with brain metastases(1), adding to the previously reported evidence for larotrectinib’s activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved; median duration of response (mDOR) of nearly three years(1) / Largest dataset with longest follow-up of any TRK inhibitor illustrates favorable safety profile across ages and tumor types(1) » more
-
Tuesday - September 24, 2019
Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital open joint lab for research of new treatments for chronic lung diseases
Investment of over USD 30 million spanning five years to research and develop new treatments for chronic lung diseases / Joint lab to broaden Bayer’s presence in the Boston ecosystem » more
-
Monday - September 23, 2019
Not intended for U.S. and UK Media
Vitrakvi® (larotrectinib) receives first tumor-agnostic approval in EU
Precision oncology treatment Vitrakvi® (larotrectinib) approved for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Vitrakvi, which was exclusively designed to treat TRK fusion cancer, is the first therapy in the EU with a tumor-agnostic indication / Larotrectinib provides high response rates and durable responses in adults and children with TRK fusion cancer, including primary CNS tumors and brain metastases / In studies, larotrectinib demonstrated an overall response rate of 72% including 16% complete responses, with 75% of patients still on treatment after one year / Larotrectinib showed a favorable safety profile, with the majority of adverse events (AEs) being grade 1 or 2; only 3% of patients had to stop therapy due to treatment-emergent AEs » more
-
Friday - September 20, 2019
Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019
Bayer data at ESMO 2019 highlights innovation in cancer research
New data for larotrectinib on durability of response in patients with TRK fusion cancer to be presented in a poster discussion on September 28 / Data from Bayer’s prostate cancer franchise to be presented, including clinical relevance of drug-drug interactions in men with nmCRPC taking darolutamide and real-world data and pain evalutation data in men with mCRPC treated with radium-223 dichloride / New analyses from the Phase II study REGOBONE evaluating the efficacy and safety of regorafenib in patients with rare locally advanced or metastatic relapsed chondrosarcoma to be highlighted in an oral presentation on September 30 » more
-
Tuesday - September 17, 2019
Not intended for U.S. and UK Media
Bayer and Informed Data Systems Inc. to develop One Drop digital therapeutics platform for multiple therapeutic areas
Equity stake in company through Series B financing of USD 20 million acquired / USD 10 million commercial licensing agreement for One Drop digital platform signed » more
-
Wednesday - September 11, 2019
Initiative offers financial support for novel approaches and enabling technologies in crop research
Bayer opens application window for Grants4Traits™ and Grants4Biologicals™ » more
-
Tuesday - September 10, 2019
Changes to Board of Management structure as of January 1, 2020:
Bayer reduces size of Board of Management from seven to five members » more
-
Tuesday - September 10, 2019
Bayer launches latest fungicide innovation, iblon™ technology
Isoflucypram, member of a newly introduced chemical subclass in the family of Succinate Dehydrogenase Inhibitors (SDHIs), is the core of iblon™ technology / iblon™ technology delivers excellent disease control leading to healthy-looking and consistently higher yielding cereal crops » more
-
Friday - September 6, 2019
Bayer showcases Root2Success for potato and sweet potato growers at congress in Rwanda:
Yields more than doubled during 4-year project with smallholder farmers » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Wednesday, October 30, 2019
Q3 2019 Quarterly Statement
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV